SCHEMBL2328642

SCHEMBL2328642

CN1CCC(C(=O)O)CC1=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
POLB P06746 4/20 0.46
BRD4 O60885 2/20 0.46
GAA P10253 1/20 0.43
RECQL P46063 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC3 O15379 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16892194 0.84 BRD4 (0.46) MAPTPOLBBRD4GAAHDAC1
SCHEMBL22234986 0.82 BRD4 (0.44) MAPTPOLBBRD4GAAHDAC1
SCHEMBL16887543 0.81 BRD4 (0.43) MAPTPOLBBRD4SMN1; SMN2HDAC1
SCHEMBL22235274 0.81 BRD4 (0.43) MAPTPOLBBRD4GAAHDAC1
SCHEMBL14636507 0.79 BRD4 (0.69) POLBBRD4GAASMN1; SMN2KDM4E
SCHEMBL31391873 0.79 BRD4 (0.46) BRD4SMN1; SMN2HDAC1HDAC2HDAC3
SCHEMBL22235293 0.79 BRD4 (0.42) MAPTPOLBBRD4SMN1; SMN2HDAC1
SCHEMBL16886317 0.79 BRD4 (0.42) MAPTPOLBBRD4GAAHDAC1
SCHEMBL30307671 0.79 BRD4 (0.63) MAPTPOLBBRD4GAARECQL
SCHEMBL15684270 0.79 BRD4 (0.63) MAPTPOLBBRD4GAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 WO claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
US-20250326726-A1 FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES SIRONAX BEIJING CO LTD (CN) 2025-10-23 US disclosed
EP-4251615-B1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2025-10-15 EP disclosed
EP-4631573-A2 TEAD INHIBITORS Orion Corporation (FI) 2025-10-15 EP disclosed
EP-4323338-B1 TEAD INHIBITORS ORION CORP (FI) 2025-10-08 EP disclosed
WO-2025103493-A1 CANNABINOID RECEPTOR 1 ANTAGONIST AND USE THEREOF 西藏海思科制药有限公司 2025-05-22 WO disclosed
WO-2025098509-A1 PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE 康百达(四川)生物医药科技有限公司 2025-05-15 WO disclosed
US-20130210798-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
CN-102918042-A 8-methyl-1-phenyl-imidazo [1,5-a ] pyrazine compounds MSD OSS BV 2013-02-06 CN disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed
EP-2534151-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MSD Oss B.V. (NL) 2012-12-19 EP disclosed
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2012-12-06 US disclosed
WO-2012149540-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE INC (US) 2012-11-01 WO disclosed
WO-2011095556-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326726-A1 FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES AIFM2, GPX4, FECH MAPT 3646/4885POLB 4494/4885BRD4 1838/4885
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS LCK, ZAP70, FYN MAPT 2491/4885POLB 3531/4885BRD4 1046/4885
US-20130210798-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1B1, GUCY1A1, GUCY1A2 MAPT 3281/4885POLB 3659/4885BRD4 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.